Virpax Pharmaceuticals Sees Stock Surge
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) experienced a significant rise in its stock shares, particularly noticeable during the premarket session. This positive movement appears to be driven by the recent announcement regarding results from a Dose Range Finding (DRF) study for Probudur.
Positive Results for Probudur
In a study conducted using minipigs, Virpax showcased that Probudur, a long-acting liposomal bupivacaine formulation, was well-tolerated without adverse effects. The primary objective of this study was to evaluate its potential for both immediate and prolonged pain relief.
Study Overview
The Dose Range Finding study aimed to assess Probudur's tolerance during an incisional wound healing model. Local injections were administered to the tissue surrounding the incision area, supporting the formulation's safety profile.
Company's Strategic Move
Jatinder Dhaliwal, the CEO of Virpax, expressed optimism about the findings, highlighting that the completion of these studies brings the company closer to filing their Investigational New Drug Application (IND) for Probudur.
Price Performance
As reported, VRPX stock has faced significant challenges over the past year, reportedly losing over 88% of its value.
Collaboration with NCATS
An important recent update from Virpax includes the extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health. This collaboration is crucial for the ongoing development of NES100, an intranasal peptide designed for managing both acute and chronic non-cancer pain.
Advancements in Pain Management
NES100, a cutting-edge enkephalin-based drug, utilizes advanced nanotechnology to improve delivery into the brain. Enkephalin serves as a natural pain-relief peptide, but its traditional administration has often proven ineffective.
Safeguarding Against Opioid Risks
Virpax employs its proprietary Molecular Envelope Technology (MET) to protect the drug during delivery via the olfactory nerve pathway, specifically targeting delta opioid receptors to reduce pain sensations. Animal model trials of NES100 have shown promising results that do not carry the common risks associated with opioids, such as tolerance and addiction.
Future Prospects
Dhaliwal emphasized that the ongoing collaboration will facilitate the advancement of NES100 through critical preclinical and clinical stages, potentially offering a safer alternative for effective pain management.
Current Stock Movements
As of the last report, shares of VRPX traded higher by an impressive 55.7%, reaching $0.9181 in the premarket. This surge in stock price reflects the market's favorable reception of the company's recent announcements and developments.
Frequently Asked Questions
What is Probudur?
Probudur is a long-acting liposomal bupivacaine formulation developed by Virpax Pharmaceuticals aimed at providing pain relief.
What was the outcome of the recent study for Probudur?
The study indicated that Probudur was well-tolerated in minipigs, with no adverse effects observed.
How does NES100 work?
NES100 uses advanced nanotechnology to enhance the delivery of enkephalin, a natural peptide, into the brain, aiding pain management without typical opioid risks.
What partnership did Virpax recently extend?
Virpax has extended its research agreement with the National Center for Advancing Translational Sciences (NCATS) to develop NES100 further.
How has VRPX stock performed recently?
VRPX stock has gained substantially, increasing by 55.7% to $0.9181 in the latest premarket session.
